Find clinical trials

Peripheral arterial disease (PAD) is a condition which leads to narrowing and blockages in the large and medium-sized arteries which supply blood to your leg which typicalling requires angioplasty treatment. The ChampioNIR DES is a stent made of metal, coated with a mesh that can expand and which contains a drug called ridaforolimus. . Ridaforolimus stops cells from growing and replicating by attaching to a protein called mTOR, meaning that cells are less likely to build up around your stent and narrow your arteries.

This Phase II study aims to evaluate the efficacy and safety of the combination of JSB462 (also known as luxdegalutamide) at 100 mg and 300 mg QD doses + lutetium (177Lu) vipivotide tetraxetan (hereafter referred as AAA617) compared with AAA617 (control) in participants with metastatic Castration Resistant Prostate Cancer (mCRPC) with prior exposure to at least 1 Androgen Receptor Pathway Inhibitor (ARPI) and 0-2 taxane regimens and to select the recommended dose of the combination for phase III. Towards that end, the totality of the efficacy, safety, tolerability and pharmacokinetic (PK) data from participants randomized in the study will be evaluated.

This study aims to determine whether a new medication, NNC6019-0001, can lower the risk of heart-related complications in people diagnosed with transthyretin amyloid cardiomyopathy (ATTR-CM), a disease that affects the heart. Participants will be randomly assigned to receive either NNC6019-0001 or a placebo, which contains no active drug. Throughout the study, all participants will continue their standard heart treatments as advised by their healthcare provider.

The study will be conducted in 2 phases: Phase 1: Dose-escalation and Dose Level Expansion, Phase 1 will determine the maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE). Phase 2: Tumor-Specific Expansions with Dose Optimization, Phase 2 will further evaluate CLIO-8221 in tumor-specific expansion cohorts to optimize dosing and assess preliminary efficacy. 

Rollover study from CLOU064J12301 (AH_238/24) – NOT RECRUITING NEW PARTICIPANTS

This is a global, phase 3 multicenter, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy, safety, and tolerability of remibrutinib in adult participants with severe chronic pruritus of unknown origins (CPUO). The design includes 4 periods, for a total duration of up to 60 weeks: Screening period: up to 4 weeks. Double-blind treatment period (treatment period 1, TP1): 24 weeks of double-blind treatment with remibrutinib or matching placebo. Open-label treatment period (treatment period 2, TP2): 28 weeks of open-label treatment with remibrutinib. The participants randomized to the placebo arm will be switched to remibrutinib at Week 24. Safety follow-up period: 4 weeks of treatment-free safety follow-up.

At the start of the trial, Patients will have genetic testing and all patients will then receive treatment with Asciminib monotherapy at 80mg daily for the first four weeks, while the genetic results are analysed. Patients are then split into high or standard risks groups based on their genetic results. Patients determined to be at standard risk will continue to receive 80mg daily Asciminib monotherapy while high risk patients will receive combination therapy of: 80mg of Asciminib daily and 50mg of Dasatinib daily. Overall treatment duration is upto 2 years.